Marizomib (NPI-0052, Salinosporamide A)
Published: Nov 4, 2009 11:33 am
| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Triphase Research and Development I Corp |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Marizomib may be used as an alternative treatment to Velcade (bortezomib), the first approved proteasome inhibitor, because it has shown significant activity against multiple myeloma that was previously resistant to Velcade. Marizomib is often administered orally or intravenously as either a single agent or in combination with other anti-cancer agents.
Clinical Trials:
For a list of clinical trials studying marizomib for the treatment of multiple myeloma, see ClinicalTrials.gov.
Updated May 28, 2013
Related Articles:
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma